APT (Adjuvant Paclitaxel and Trastuzumab): Paclitaxel Plus Trastuzumab in HER2-Positive Node-Negative Early Breast Cancer

Primary endpoint (Survival free from invasive disease): 98.7% at 3 years (95% CI 97.6–99.8) Statistical test: vs null hypothesis of 9.2% 3-year event rate; P<0.001 Key secondary (Recurrence-free interval): 99.2% at 3 years (95% CI 98.4–100) — exploratory Sample size: N=406 treated/analyzed Safety signal: Symptomatic congestive heart failure (0.5%); grade 3 neuropathy (3.2%)

Clinical Bottom Line

The APT trial demonstrated that a de-escalated adjuvant regimen of weekly paclitaxel plus trastuzumab — without anthracyclines or additional cytotoxic agents — achieved outstanding disease-free survival in patients with small, node-negative, HER2-positive breast cancer. With only twelve invasive-disease events among 406 treated patients at a median follow-up of four years, the regimen far exceeded its prespecified efficacy threshold, establishing itself as a practice-defining option for this lower-risk population.

This trial fundamentally changed the adjuvant treatment algorithm for small, node-negative, HER2-positive tumors. Before APT, these patients faced a dilemma: the standard anthracycline- and taxane-based regimens with trastuzumab carried meaningful toxicity for a population with a relatively favorable prognosis, yet omitting HER2-directed therapy risked undertreatment given the known aggressive biology of HER2-positive disease. APT provided the first prospective evidence that an abbreviated, non-anthracycline chemotherapy backbone paired with trastuzumab could deliver excellent outcomes with a substantially lower toxicity burden, and it has become the preferred regimen for this population in major guidelines.

The safety profile was favorable. No treatment-related deaths occurred, and the most clinically significant toxicities — cardiac dysfunction and peripheral neuropathy — were infrequent and manageable. The low rate of symptomatic heart failure is particularly noteworthy given the avoidance of anthracyclines. Cardiac monitoring remains essential, but the overall tolerability of this regimen makes it well-suited to a population where overtreatment is a genuine concern.

Trial Overview

Study Design

• Trial name and registration: APT — Adjuvant Paclitaxel and Trastuzumab (NCT00542451)
• Design: Single-group, multicenter, investigator-initiated study; open-label, uncontrolled; final analysis
• Randomization: Not applicable (single-arm study)
• Setting: HER2-positive breast cancer, adjuvant; tumors up to 3 cm, node-negative (or one micrometastasis); predominantly stage I
• Enrollment period and sites: October 9, 2007, through September 3, 2010; multiple centers

Patient Population

• Key eligibility: Pathological diagnosis of adenocarcinoma of the breast; HER2-positive (IHC 3+ or FISH HER2/CEP17 ratio ≥2.0); invasive tumor ≤3 cm; node-negative (amended to allow one lymph-node micrometastasis with completed axillary dissection and no further involvement); LVEF ≥50%
• Biomarker selection: HER2-positive (immunohistochemical staining for HER2 protein of 3+ intensity or amplification of HER2 gene on FISH with ratio of HER2 to CEP17 ≥2.0)
• Sample size flow: Enrolled: 410 → Began protocol therapy: 406 → Analyzed: 406

Baseline Characteristics

A total of 49.5% of patients had tumors that measured 1 cm or less, and 8.9% had tumors that measured between 2 and 3 cm.

Treatment Protocol

Treatment Regimen: Paclitaxel + Trastuzumab (n=410 enrolled; n=406 treated; n=406 analyzed)

Paclitaxel 80 mg/m² IV weekly for 12 weeks plus trastuzumab (loading dose 4 mg/kg IV on day 1, then 2 mg/kg weekly for 12 doses), followed by trastuzumab monotherapy (weekly or 6 mg/kg every 3 weeks) for 40 weeks to complete 1 year. - Dose and schedule: Paclitaxel 80 mg/m² IV weekly × 12 weeks; Trastuzumab loading dose 4 mg/kg IV day 1, then 2 mg/kg weekly × 12 doses; then trastuzumab continued weekly or 6 mg/kg every 3 weeks × 40 weeks - Treatment duration: 52 weeks - Treatment completion: 356 (87.7%) completed all 52 weeks of therapy - Discontinuations: 24 patients discontinued therapy because of protocol-specified toxic effects, and 6 patients discontinued because of other toxic effects; 17 (4.2%) withdrew consent; 10 (2.5%) were lost to follow-up - Median treatment duration: Not reported in this publication - Median relative dose intensity: Not reported in this publication

There was no comparator arm in this study.

Efficacy Outcomes

Primary Endpoint: Survival Free from Invasive Disease (Disease-Free Survival)

Definition: Events of invasive disease (recurrence and new invasive disease) and death from any cause, as defined by the standardized efficacy end-points (STEEP) criteria.

Analysis population: All 406 patients who began protocol therapy (intention-to-treat)

Statistical method: Group-sequential Poisson test based on total patient-years of follow-up; Kaplan–Meier product-limit method for estimation. The null hypothesis was a 3-year event rate of 9.2%; a 3-year rate of 5% was considered successful. If ≤39 events were observed at the final analysis (1600 patient-years), the regimen was considered effective.

Median follow-up: 4.0 years (maximum follow-up: 6.2 years; total: 1605 patient-years)

Result: 3-year survival free from invasive disease: 98.7% (95% CI, 97.6 to 99.8) Events: 12 in 406 patients (3.0%) Statistical test: The null hypothesis of a 9.2% 3-year event rate was rejected (P<0.001).

Event Detail

Exploratory Endpoints

Recurrence-Free Interval

Definition: Local or regional recurrence, distant recurrence, or death from breast cancer (unlike recurrence-free survival, did not include death from cancer other than breast cancer), according to STEEP criteria.

Analysis population: All 406 patients who began protocol therapy (intention-to-treat)

Result: 3-year recurrence-free survival: 99.2% (95% CI, 98.4 to 100)

This endpoint was exploratory and was not formally tested in the statistical hierarchy.

Safety

Safety Population

Paclitaxel + Trastuzumab: n=406

Safety Summary

Standard summary safety metrics (any-grade AE rates, overall grade ≥3 rates, serious AE rates, treatment-related AE rates, dose reduction rates, and dose interruption rates) were not reported in this publication. The following metrics were available:

• Treatment-related deaths: 0

• Discontinuations due to toxicity: 24 (protocol-specified toxic effects) + 6 (other toxic effects)

• Treatment completion rate: 356 (87.7%) completed all 52 weeks

Grade ≥3 Adverse Events of Clinical Significance

The source reported grade 3 and grade 4 events separately:

Note: The source (Table 3) reported most common adverse events of grade 2 or higher during protocol therapy. No grade 4 neurotoxic effects were reported (0%; 95% CI, 0 to 0.9).

Adverse Events of Special Interest

⚠️ Cardiac Toxicity: Special Interest Signal

Symptomatic congestive heart failure (grade 3 systolic dysfunction of the left ventricle):

• Grade 3: 2 (0.5%; 95% CI, 0.1 to 1.8)

• Both events occurred during active therapy — at 6 months and 11 months — and both patients recovered after the discontinuation of trastuzumab

Clinically significant asymptomatic decline in ejection fraction:

• Any grade: 13 (3.2%; 95% CI, 1.7 to 5.4)

• Led to interruption in treatment with trastuzumab

• Clinical implication: The cardiac signal was low, consistent with the avoidance of anthracyclines in this regimen. Nonetheless, LVEF monitoring per standard HER2-targeted therapy guidelines remains essential. The finding that both symptomatic heart failure events resolved after trastuzumab discontinuation is reassuring.

Neuropathy

During 12 weeks of combined paclitaxel-trastuzumab therapy:

• Grade 3: 13 (3.2%; 95% CI, 1.7 to 5.4)

• Grade 4: 0 (0%; 95% CI, 0 to 0.9)

Note: Table 3 reports neuropathy grade 3 as 14 (3.4%) during the full 52 weeks of protocol therapy. The discrepancy likely reflects the different time frames (12-week combination phase vs. full 52-week treatment period).

Allergic Reactions

A total of 7 patients had grade 3 or grade 4 allergic reactions to the study treatment, and only 1 of these patients was able to complete treatment.

Deaths

• Total deaths: 2 (0.5%) — both from causes unrelated to breast cancer (ovarian cancer at 13 months; stroke at 71 months)

• Breast-cancer-related deaths: 0

• Treatment-related deaths: 0

Subgroup Analyses

Subgroup analyses by tumor size (≤1 cm vs >1 cm) and hormone-receptor status (positive vs negative) showed that the rate of recurrence in these subgroups was lower than anticipated. The lower boundaries of the 95% confidence intervals for survival free of invasive disease at 3 years in all subgroups exceeded 96.0%.

These subgroup analyses were exploratory and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating. Importantly, the consistently excellent outcomes across all subgroups — including both tumors ≤1 cm and >1 cm, and both hormone-receptor–positive and hormone-receptor–negative disease — suggest that the de-escalated regimen is effective across the range of patients enrolled.

Key Comparator Trials

Comparator Table

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

The APT trial occupies a unique position in the HER2-positive adjuvant landscape because it deliberately enrolled the population that the larger escalation trials (APHINITY [4], HERA, BCIRG 006 [5]) either excluded or represented as a minority subgroup. Patients with small, node-negative, HER2-positive tumors were historically undertreated because standard anthracycline-taxane regimens seemed excessive for their risk level, yet the aggressive biology of HER2-positive disease warranted targeted therapy.

The BCIRG 006 trial [5] provided early evidence that a non-anthracycline, carboplatin-based regimen (TCH) with trastuzumab could achieve comparable efficacy to anthracycline-containing regimens with a better cardiac safety profile. The APT trial took the de-escalation concept further by eliminating both anthracyclines and carboplatin, relying solely on weekly paclitaxel as the chemotherapy backbone. The resulting 3-year DFS of 98.7% — in a population where the null hypothesis assumed a 9.2% event rate — provided compelling evidence that less chemotherapy, when combined with effective HER2-directed therapy, is sufficient for appropriately selected lower-risk patients.

Grey Zones and Unanswered Questions

1. Single-arm design without a comparator. The absence of a randomized control arm means we cannot quantify the incremental benefit of adding trastuzumab to paclitaxel in this population, nor can we determine whether the excellent outcomes were due to the regimen, the favorable biology of the selected population, or both. The null hypothesis rate of 9.2% was derived from historical data and may overestimate the expected event rate in a contemporary cohort.

2. Patients with tumors >3 cm and node-positive disease were excluded. The APT regimen cannot be extrapolated to higher-risk populations. Clinicians managing patients with larger tumors or nodal involvement should not generalize these results beyond the enrolled population. The upper boundary of tumor size (3 cm) was a pragmatic cutoff without biological justification — it remains unclear whether patients with T2 tumors in the 3–5 cm range would achieve similar outcomes.

3. The contribution of trastuzumab vs paclitaxel alone is unknown. Without a paclitaxel-only arm, the trial cannot isolate the effect of trastuzumab. It is plausible — though unproven — that some patients with very small (T1a/T1b), hormone-receptor–positive tumors might have excellent outcomes with surgery and endocrine therapy alone, without chemotherapy or HER2-targeted therapy.

4. Long-term cardiac outcomes beyond four years are not reported in this publication. While the 0.5% rate of symptomatic heart failure is reassuring, the median follow-up of 4.0 years may be insufficient to capture late cardiac effects, particularly in patients who subsequently receive cardiotoxic therapies for other indications. The protocol was amended to extend follow-up to 10 years, and longer-term data will be important.

5. Optimal treatment for patients who recur after APT is undefined. The small number of recurrences (12 events) precludes meaningful analysis of post-recurrence outcomes. Whether patients who recur after this de-escalated regimen should be treated differently from those who recur after standard anthracycline-trastuzumab-based regimens is unknown.

6. The role of adjuvant pertuzumab in the APT-eligible population is unclear. The APHINITY trial showed no benefit in node-negative patients. Whether adding pertuzumab to the APT backbone would improve outcomes for any subgroup within this low-risk population is untested, and the APT results suggest the incremental benefit would likely be negligible.

Clinical Implications

Rationale and Clinical Context

Before the APT trial, clinicians treating patients with small, node-negative, HER2-positive breast cancer faced a genuine clinical dilemma. The pivotal adjuvant trastuzumab trials (HERA, NSABP B-31, NCCTG N9831, BCIRG 006) enrolled predominantly higher-risk, node-positive patients and used multi-agent chemotherapy backbones including anthracyclines. Applying these intensive regimens to patients with T1a/T1b node-negative tumors exposed them to meaningful risks — cardiotoxicity, secondary leukemia, febrile neutropenia — for a disease that, even without treatment, might have a relatively favorable prognosis.

However, retrospective data showed that even small HER2-positive tumors carried a non-trivial recurrence risk, suggesting that omitting HER2-directed therapy entirely was also problematic. The APT trial was designed to test the hypothesis that a shorter, less toxic chemotherapy backbone (12 weeks of weekly paclitaxel) combined with a full year of trastuzumab could provide adequate disease control in this population. The 3-year DFS of 98.7% resoundingly answered this question and established the APT regimen as the de-escalation standard for low-risk HER2-positive early breast cancer.

Monitoring and Long-Term Follow-Up

• Cardiac monitoring: LVEF assessment should be performed at baseline and at regular intervals during and after trastuzumab therapy. Symptomatic heart failure occurred in 2 patients (0.5%), both during active therapy and both reversible. Asymptomatic LVEF decline led to trastuzumab interruption in 13 patients (3.2%). The anthracycline-free backbone likely contributed to the favorable cardiac profile.
• Neuropathy monitoring: Grade 3 neuropathy occurred in 13–14 patients (3.2%–3.4%) and was the most common non-hematologic grade 3 toxicity. Patients should be assessed for peripheral neuropathy at each visit during the paclitaxel phase, with dose modifications as indicated.
• Long-term follow-up: The protocol was amended to extend follow-up to 10 years. Given that late recurrences of HER2-positive breast cancer — particularly in the hormone-receptor–positive subgroup — can occur beyond 5 years, continued surveillance is warranted.

De-Escalation Considerations

The APT trial is the paradigmatic de-escalation trial in HER2-positive early breast cancer. Its results demonstrate that not all HER2-positive patients require anthracycline-based polychemotherapy. The critical clinical question is patient selection:

• Strong candidates for APT: Node-negative, tumor ≤2 cm, any hormone-receptor status. This represents the core population studied and where the data are strongest.
• Reasonable but less certain: Tumors 2–3 cm, node-negative. Only 36 (8.9%) of enrolled patients had tumors in this range, and subgroup data are limited.
• Not candidates for APT: Node-positive patients (other than isolated micrometastases). These patients should receive standard multi-agent regimens with or without pertuzumab.
• Uncertain territory: T1a tumors (>0.1 to ≤0.5 cm). Whether even the APT regimen represents overtreatment for the smallest HER2-positive tumors is debated, though the trial enrolled 68 (16.7%) patients with T1a disease and the overall results were excellent.

Unanswered Questions

• Whether the 10-year follow-up data (protocol amendment in progress) will reveal late recurrences that alter the risk-benefit calculation, particularly in hormone-receptor–positive patients.
• Whether biomarker-based approaches (genomic assays, tumor-infiltrating lymphocytes, PIK3CA mutation status) could further refine patient selection for de-escalated therapy.

Regulatory and Guideline Status

Regulatory

• FDA: The APT trial regimen does not have a specific FDA-approved indication as a named regimen. Trastuzumab (Herceptin) is FDA-approved for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; or with docetaxel and carboplatin; or as a single agent following multi-modality anthracycline-based therapy [2]. The APT regimen represents an off-label but widely adopted and guideline-endorsed treatment approach.
• EMA: Trastuzumab is approved for early HER2-positive breast cancer. The specific APT regimen is not named in the label. Regulatory status should be verified with current EMA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: The NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [3] include paclitaxel plus trastuzumab (the APT regimen) as a preferred adjuvant regimen for patients with small (≤2 cm preferred, up to 3 cm), node-negative, HER2-positive breast cancer. This regimen is listed as a Category 2A recommendation.
• ASCO/St. Gallen: The APT regimen is widely endorsed by international guidelines as the preferred de-escalated approach for low-risk HER2-positive early breast cancer.

Companion Diagnostics

HER2 positivity must be confirmed by validated testing: immunohistochemistry (IHC 3+) or fluorescence in situ hybridization (FISH) demonstrating a HER2/CEP17 ratio ≥2.0. The APT trial required HER2 confirmation but did not mandate central testing.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-141. doi:10.1056/NEJMoa1406281
2. Herceptin (trastuzumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122-131. doi:10.1056/NEJMoa1703643
5. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283. doi:10.1056/NEJMoa0910383